Public
PharmaPack Europe Events
PharmaPack Europe Locations
PharmaPack Europe News
Pharmapack Europe Videos
If this is your company, CONTACT US to activate Packbase™ software to build your portal.
At Pharmapack we are increasingly aiming to bring sustainability into the event, into the conversations people have, into the content we present and into the running of the show itself. This year we are working with a number of Sustainability Partners to help make this possible. In this interview, we speak with Adelphe, one of our Sustainability Partners for Pharmapack 2025.
In this interview, Adelphe representative Vesna Reynal, Health Market Manager, highlights what Adelphe consider the most pressing concerns in sustainability in pharmaceutical packaging today.
1. What do you think is the most pressing sustainability concern or challenge in pharmaceutical blister packaging today?
The main sustainability challenge in pharmaceutical blister packaging lies in reducing plastic and aluminium waste while maintaining the required protective barrier properties and strict safety and regulatory standards. Developing recyclable or mono-material alternatives is crucial to reducing environmental impact without compromising safety and compliance.
2. What sustainability trends are you seeing from packaging companies moving into the next few years?
Sustainability trends in packaging are growing, with a focus on recyclable mono-materials, bio-based alternatives (such as renewable materials) and lightweight design to reduce environmental impact as well as emphasis on reusable packaging. Packaging companies will invest in solutions that meet both sustainability goals and evolving global regulatory standards for packaging waste and emissions.
3. Why are events such as Pharmapack important platforms for sustainability in the industry?
Because they bring together stakeholders to share innovations, discuss challenges and collaborate on sustainable packaging solutions. These gatherings foster knowledge exchange and drive collective action towards reducing environmental impact.
4. What are you most looking forward to at Pharmapack 2025?
As Informa’s sustainable partner, Pharmapack represents for Adelphe (Citeo Group) an opportunity to engage with stakeholders, whom we help to reduce the environmental impact of their packaging through our R&D eco-design efforts, tools, and services. We are pleased to announce the release beginning 2025 of the Guide of Pharmaceutical Blister, which is the result of a five-year working group. As member of the jury, I am also delighted to present the Eco Design Award.
Make sure to attend the Sustainability Track at Pharmapack in Paris this year. For more information see here.
This interview first appeared on CPHI Online.
Pharmapack Europe & CPHI have outlined key trends for pharma in 2025, highlighting the return of funding liquidity—via increased VC investments and PE capital for M&A—alongside enhanced supply chain resilience as “The Good”. The ongoing uncertainty around the intentions and practical implications of the BIOSECURE ACT is “The Bad”, with Donald Trump’s presidential return once again “the Great Known Unknown”. The predictions come ahead of this month’s Pharmapack, where pharma’s momentum from the latter half of 2024 is expected to continue with a new record attendance. In particular, the event has seen a rapid increase in start-up companies attending – more than doubling in the last 24-months – as European markets are expected to drive forward innovation in drug delivery and packaging in the next 12-months.
Amid uncertainties facing U.S. pharma companies, the industry’s strong fundamentals have fostered widespread optimism. Experts at CPHI and Pharmapack Europe predict a landmark year in 2025, driven by a biologics boom, robust pipelines, and expanding GLP-1 profits. Efforts to establish new manufacturing hubs and supply chains are accelerating, with outsourcing cemented as a key driver of drug discovery, development, and commercial supply.
Perhaps most significantly, while many industry analysts widely caution us to "expect the unexpected" with the second coming of a Donald Trump presidency, the market has responded with surprising optimism. There is even a measured "wait-and-see" attitude toward the controversial appointment of Robert F. Kennedy Jr. Remarkably, eight years after our initial New Year’s prediction release on a Trump presidency as the "great unknown"[1], this 2.0 iteration has been met with a surprisingly composed response from the pharma sector. The takeaway? While changes are anticipated and the direction remains difficult to forecast, the industry appears confident that there will be more winners than losers, regardless of the path taken during the next administration.
In Europe, the Pharmapack Report identified Île-de-France as a growing MedTech innovation hub for 2025. The region, which will host Pharmapack Europe 2025 [January 22/23] later this month, was highlighted as the ideal location for start-up device and MedTech companies, thanks to its combination of funding opportunities, availability of R&D staff and, crucially, a strong base of pharma manufacturing and packaging resources.
This is particularly significant for device development and filling, with the region expected to play a sizable role in both biologic device design and contract filling. The ongoing demand for GLP-1 drugs is predicted to cause biotechs with clinical filling needs – such as oncology targets with smaller volumes – to face delays as GLP contracts hoover-up the majority of aseptic filling capacities. The result is that we will see biotechs widening supplier networks and potentially even big pharma searching for new partners for GLP-1s [especially with Catalent’s ongoing uncertainty]. Consequentially, contract and device filling is predicted to be a rapid growth area at Pharmapack.
Pharmapack experts point to the shortage of experienced aseptic fill-finish capacity, which inevitably means that medium and small pharma have to look at alternative supply options. The other driver is the generic GLP-1s entering the market this year, adding further resource pressure – particularly as what pharma needs is end-to-end capabilities in drug-device combinations, including assembly, and this is still rare among contract packaging CDMOs.
BIOSECURE’s practical implications will continue to evolve until the Bill is either passed [or dropped] in some form. However, the industry is already adjusting for the medium-term changes, with discovery chemistry services switching to both Europe and particularly Indian CROs. In contrast, development and commercial contracts are being more widely shared with opportunities abounding, particularly for those investing in advanced biologics manufacturing that lowers costs per gram.
The short term one year fall-out is likely to be a rapid increase in drug discovery conducted in India. What happens in the medium term with a Trump presidency and innovative drugs ‘made in the US’ will be intriguing, as potentially pharma and biotech opt to have some MAb plants in country.
Pharmapack Europe expects over 6000 attendees and over 370 exhibiting companies this year, with significant growth in early-stage companies participating. Its Start-Up Hub will host over 20 emerging companies, with increasing interest from German and Swiss executives seeking new development and licensing opportunities in device and packaging innovations.
The full results of the Pharmapack Report predictions are available on CPHI Online. Click here for a full breakdown of conference topics, or more information on the event please visit: www.pharmapackeurope.com/en
New research released ahead of Pharmapack Europe – the continent’s largest partnering event for medical device and packaging innovation – has ranked the Basel region as the most attractive destination in Europe for launching a new drug device company. The study surveyed over 280 global pharmaceutical executives, asking them to identify the best location based on factors such as plant costs, access to skilled personnel, and ongoing operational expenses.
Basel emerged as the clear leader, selected by one-third of respondents, outperforming Lombardy (18%), Catalunya (17%), the UK’s "Golden Triangle" (15%), and Baden-Württemberg in Germany (14%).
The event, which takes places later this month at the Paris Expo (January 22/23, 2025) is renowned as Europe’s premier pharmaceutical hub and empowers start-up innovators to meet with larger drug device and big pharma partners. Many of the breakthrough technologies in device design and sustainable packaging first gained industry attention at earlier editions of Pharmapack.
“As one of the few places where early-stage innovators can meet with investors and scale-up partners, we play a vital role in propagating drug delivery innovation,” commented Sherma Ellis-Daal, Brand Director at Pharmapack Europe. “This research identifies the optimal locations for discovering and developing the next generation technologies for a novel device or new packaging - from concept to commercialisation. In fact, one of the major impediments to development success is simply having the access to the right partners to scale, which is why we are encouraging innovators from across these major European centres to attend the event.”
In a further boost to industry prospects in Switzerland and Germany were selected as the two regions best to build a new biomanufacturing facility. Basel was selected as the clear winner, despite higher labour costs, due to its ‘unrivalled access to qualified personal and quality of research firms and infrastructure’.
Pharmapack Europe expects over 6,000 attendees and over 370 companies this year, with significant growth in early-stage companies participating. Its Start-Up Hub will host over 20 emerging companies, with increasing interest from German and Swiss executives seeking new development and licensing opportunities in device and packaging innovations.
Stèfan Halbherr, CEO, InnoMedica a Swiss-based biotech and a Start-up Market innovator, attending Pharmapack to meet new clinical and commercial-scale partners for its nanocarriers filling technology, added: “It’s not surprising to us at all. Switzerland has a tremendous history of pharmaceutical innovation and highly qualified personnel. However, what is often underappreciated outside the country is the access to precision engineering available here. With many new devices and innovations targeting smaller patient cohorts for precision and personalized medicine applications, we need a fresh approach to device design and manufacturing flexibility. Switzerland offers an exceptional foundation in manufacturing precision machinery. For example, to develop our unique approach to nanoparticle device filling, we collaborated with a manufacturer specializing in the production of small, highly precise machinery traditionally used in watchmaking. Moving forward, you’ll see smaller companies leading the next generation of med-tech innovation by adopting techniques from other industries and applying them to Switzerland’s world-class biomedical infrastructure.”
The full results of the Pharmapack Report 2024 and Index will be released during the event on CPHI-online. Click here for a full breakdown of conference topics, or more information on the event please visit: www.pharmapackeurope.com/en
HEALTH PRODUCT AWARDS
ECO-DESIGN WINNER
Rotor Print for Recyclable Sticks
HIGHLY COMMENDED
Klim-Loc Medical, LLC for Klim-Loc Needleless Medical Vial
PATIENT-CENTRIC DESIGN WINNER
Dr. Ferrer Biopharma for GentleMist Technology
EXHIBITOR INNOVATION
PACKAGING INNOVATION winner
Nissha Europe GmbH for Pulp-Injection Autoinjector Component
HIGHLY COMMENDED
CORADIN for the GREENIS Dispenser
START-UP INITIATIVE WINNER
Capa Valve Ltd for Capa Valve
Paris 24th January 2024: Pharmapack Europe (#PharmapackEU) announces the winners of the prestigious 2024 Pharmapack Awards spanning four categories across two dedicated awards.
The Health Product Awards are open to the entire pharma industry – with winners in ‘eco-design’ and ‘patient-centric design’ – while the Exhibitor Awards celebrate excellence ‘packaging’ and ‘start-up’ innovation. So high was the standard in the packaging innovation and eco-design categories that the judges also bestowed a Highly Commended for two second placed entries.
A new injection moulding technology that uses pulp instead of plastics and a dispenser that revolutionizes the way medications are delivered intra-nasally were both recognised for their innovative approach to product development at the prestigious Pharmapack Awards ceremony. Two awards were also bestowed, one for a system that affords quick and easy administration of combinations of lyophilised injectable drugs, and the second for a mono material, recyclable stick for pharmaceutical products.
Finally, a needleless vial and cap system, and a dispenser that offers more precise dispensing were highly commended for their innovations.
In the Packaging Innovation section of the Exhibitor Innovation Category, Nissha Europe was selected as the winner for the development of a Pulp-Injection Autoinjector Component - a new injection moulding technology that uses pulp instead of plastics.
Pulp-Injection is suitable for device components as well as secondary packaging. It mainly utilises pulp and starch, which results in a significant reduction in plastic use. In addition, components made in this way can be recycled within a standard paper recycling system. Yet, thanks to its rigidity, Pulp-Injection can achieve the complex design and high dimensional accuracy.
Such was the high standard of this year’s entries for this section of the Awards that the judges Highly Commended CORADIN for its GREENIS dispenser. As well as being designed to aid the accurate dispensing of serums and creams it is also made from 75% post-consumer recycled plastic.
The Start-Up Innovation Award went to Capa Valve Ltd for a system that allows the compartmentalisation of a standard syringe into a dual-chamber device. The Capa Valve involves the installation of two small parts within existing standard syringes suitable for prefilled applications.
Currently, there are a few companies offering dual chamber syringes for either sequential delivery liquids or premixing of a diluent and lyophilised drug – largely due to their cost and perceived complexity. However, the key feature of the Capa Valve system is that it can be produced at a comparatively low cost for any standard size syringe utilising known fill/finish technology to provide a range of functionality.
The Patient-Centric Design award was taken by Dr. Ferrer Biopharma, the company impressed the judges with its GentleMist Technology (GMT). This cutting-edge drug delivery device revolutionizes the way medications are delivered intra-nasally, offering enhanced comfort, targeted drug delivery and therapeutic benefits. Traditional nozzles often generate discomfort and pain due to the pressure exerted during administration, thus hindering patient compliance and adversely affecting the overall treatment experience. GMT addresses this challenge by utilizing advanced fluid dynamics principles and engineering expertise focusing on a more gentle and effective nasal spray nozzle.
In the Eco-Design section, the clear winner was Rotor Print for its development of a recyclable stick suitable for a wide range of current pharmaceutical products and applications.
Most conventional sticks are composed of three, four or even five layers of different materials, typically combinations of polyester, aluminum, paper and polyethylene. This approach means these structures cannot be recycled as it is impossible to separate the different layers. Rotor Print solved this problem by creating a new stick comprising three layers of the same material, making it completely recyclable. In addition, this new design can be used in the same processes as current, non-recyclable sticks, meaning laboratories can make a beneficial switch without any large investment in new machinery.
This is, in fact, the second year in a row that Rotor Print has seen its innovative approach to pharma packaging rewarded. In 2023 it received an Award for developing a high grade 100% PET blister that provides an equal barrier to the traditional aluminum lid or PVC.
The judges also highly commended Klin-Loc Medical for its Needless Medical Vial – the only vial and cap system that is can be packaged during the Fill/Finish process and delivered as a completely needleless package. Its patented composition features a medical grade polymer threaded nipple affixed to an elastomer septum. It only requires a flip of the Flip-Off cap and a twist of the Luer-Lock (threaded) syringe to gain access to the contents.
Commenting on the innovation displayed in this year’s Pharmapack Europe Awards, Tara Dougal, Content Director - Pharma at Informa, added: “What so impressive about our 2024 winners is that all the entries are advancing technologies that either bring about vital improvements in greener production, or are putting the patient front and centre of the development process. I congratulate all our winners on their commitment and contributions to the industry.”
-ENDS-
Notes to editors
About Pharmapack
Launched in 1997, Pharmapack is the leading European event for Pharmaceutical Packaging, Drug Delivery, Medical Devices and Machinery. In the past 25+ years, the event has grown from a conference with a small table-top exhibition, to an event hosting 370+ exhibitors and welcoming attendees from 75 different countries.
At the heart of Pharma
Pharmapack Europe (24-25 Jan, 2024 at Paris Expo, Porte de Versailles - Hall 7.2, Paris). CPHI Japan (17-19 April, 2024 at the Big Sight Exhibition Centre – Tokyo, Japan); CPHI North America (7-9 May, 2024 at Pennsylvania Convention Center, United States); CPHI China (19-21 June 2024 at SNIEC – Shanghai, China); CPHI South East Asia (12-14 Jul 2024 at QSNCC, Bangkok, Thailand); CPHI Milan (8-10 October 2024 at Fiera Milano – Milan, Italy); CPHI & PMEC India (26-28 November 2024 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India); with support from year-round pharma news, products and services at CPHI Online.
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
For more information, please visit www.informamarkets.com.
For media enquiries, please contact:
Alex Heeley or Nidhi Narain
De Facto Communications
T: +44 (0) 203 735 8165 / +44 (0) 7769015043
Paris, 24th January 2024: The industry is in buoyant mood at the opening of Pharmapack Europe (January 24/25) – the event at heart of the drug delivery and packaging industry – as its annual industry report predicts significant innovation in inhaled pulmonary and intra nasal drug delivery in 2024.
The Paris based event showcases the latest innovations in the pharmaceutical packaging and drug delivery, with industry leaders gathered to debate how to meet demand from a resurgent industry.
The Pharmapack report, which envisages high growth for both sectors in the year ahead, was compiled from a 200 strong industry survey, with additional analysis from Pharmacentric Solutions, Springboard, and Team Consulting.
One major shift identified was the evolution of inhalation device innovation, which is moving beyond just asthma and COPD, with the emergence of alternative therapies for conditions such as lung cancer, idiopathic pulmonary fibrosis, and Parkinson’s disease. Device development is now tailored to meet the specific requirements of these new therapy areas, with examples including intra nasal drug delivery for both liquid and dry powder dose forms targeting CNS and systemic delivery – often for products that were previously only able to be delivered with injectables.
Pharmapack Europe is also widely seen as a leading indicator of industry prospects ahead for the drug delivery and packaging market. The event expects to report a record attendance of over 5500 attendees and more than 270 exhibitors.
“The very strong turnout we see this week is sign of increased positivity across the industry, with executives in drug delivery and packaging companies actively seeking new partners and looking to increase outsourcing in 2024. There is a real desire to explore new capabilities and solutions to meet rising demand in the next few years,” commented Laura Indriksone, Brand Manager at Pharmapack Europe.
Emphasising the returning confidence seen at the event, the report’s 'drug delivery innovation' and 'sustainability' index both reported record highs earlier this month. Additionally, the report highlights the increasing preference for novel auto-injector development over on-body devices, due to lower costs and ease of use. Despite the number of products in development, on-body devices have proven to be more complex for users – involving challenges such as skin cleaning, adhesive peeling, and prolonged wearing – and injectables are forecast to cannibalise a greater share of R&D in the next year. Investment is now targeting projects that can help lower overall costs, while unsurprisingly, auto-injector innovation for GLP-1 drugs was identified as a particularly ‘hot area’ for the year ahead.
Finally, the Pharmapack Report underscored the absolute importance of partnerships and collaboration in driving device innovation; revealing that most companies are now running development projects using partnership models to improve efficiency, drive down costs, and rapidly reach important milestones.
“One of the big success this year is the Start-Up Hub, which continues to grow. It is this emerging ecosystem across devices and packaging that is creating such excitement for the year ahead. We expect to see many new development projects launched, increasingly diverse supplier lines to support the widening innovation base, but alongside this, a continued concerted effort to improve the patient experience and sustainability. The feedback from the show floor is that it’s one of the most exciting periods the industry has ever seen – with big strides expected in the years ahead,” added Indriksone.
The full results of the Pharmapack Report 2024 and Index are available on CPHI Online and for more details on registering for next year’s event – with exhibitor space already limited – please visit: https://www.pharmapackeurope.com/en/exhibit/exhibit/book-your-stand.html
-ENDS-
Notes to editors
About Pharmapack
Launched in 1997, Pharmapack is the leading European event for Pharmaceutical Packaging, Drug Delivery, Medical Devices and Machinery. In the past 25+ years, the event has grown from a conference with a small table-top exhibition, to an event hosting 370+ exhibitors and welcoming attendees from 75 different countries.
At the heart of Pharma
Pharmapack Europe (24-25 Jan, 2024 at Paris Expo, Porte de Versailles - Hall 7.2, Paris). CPHI Japan (17-19 April, 2024 at the Big Sight Exhibition Centre – Tokyo, Japan); CPHI North America (7-9 May, 2024 at Pennsylvania Convention Center, United States); CPHI China (19-21 June 2024 at SNIEC – Shanghai, China); CPHI South East Asia (12-14 Jul 2024 at QSNCC, Bangkok, Thailand); CPHI Milan (8-10 October 2024 at Fiera Milano – Milan, Italy); CPHI & PMEC India (26-28 November 2024 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India); with support from year-round pharma news, products and services at CPHI Online.
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
For more information, please visit www.informamarkets.com.
For media enquiries, please contact:
Alex Heeley or Nidhi Narain
De Facto Communications
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
Pharmapack Europe 2022 will open in May (18-19) with connectivity, sustainability and user experience identified as the key trends in 2022 influencing innovation across pharmaceutical packaging and drug delivery.
The event – which unites major players in pharmaceutical packaging, drug delivery, medical devices and machinery – returns to the Paris Expo, Porte de Versailles (Hall 7.2) and will see 5000 attendees and some 300+ companies exploring next generation technologies and looking ahead to debate the major industry developments and growth opportunities.
Pharmapack Europe will be held as Smart Event to enhance the benefits for global attendees, providing a hybrid experience that extends the value of Pharmapack beyond the two days in Paris. One week prior to the event, and for one week post, attendees will be able to access a dedicated online platform with bespoke content, analysis and networking. This gives additional opportunities to connect and create meetings outside of the event, increasing the number of companies attendees can meet with, while maximising invaluable ‘at event’ time.
The agenda, in response to industry needs, will span three core tracks: Design & Development, Sustainability, and Combination Products & Biologics. Speakers include a ‘who’s who’ of packaging and delivery heavyweights – with market analysts, regulatory experts and executives from some of the sector's most innovative companies and emerging start-ups.
“As we emerge out of the pandemic, we are seeing a significant number of opportunities for drug delivery and packaging companies. The key focus for industry is shifting towards more connected devices, improving the overall patient experience and, of course, how we can overcome the next big challenge in ensuring pharma is a more sustainable industry. What has underpinned these positive developments is more diverse partnering and sharing of insights – which is why we have spent the last few months aligning the event with everything the industry needs to prosper,” commented Sherma Ellis-Daal, Brand Manager at Pharmapack Europe.
The Design & Development Track features insights from device guru, Thomas Watts, Engineering Consultant at Team Consulting, who explores the Challenges of Cloud Connectivity. In particular, he will discuss how innovators can avoid many of the common pitfalls faced when integrating connectivity into novel devices.
Two hot areas likely to significantly impact all industry thinking in the next year are how to make packaging both more eco and user-friendly. Eco design analysis will be provided by speaker Romane Osadnick – Key Account Manager, Adelphe – as he explores how to comply with regulatory requirements for the application of Eco-Design in Pharmaceutical Packaging. From the consumer sector’s perspective, Clare Beddoes, Senior Insights Research Consultant, Cambridge Design Partnership and Ben Kubler, Consultant Industrial Designer, Cambridge Design Partnership will breakdown the current landscape on how Drug Delivery is Evolving the User Experience.
In contrast, the highly anticipated second track, will delve into the defining challenge of the next decade, exploring sustainability implications for devices and packaging. Tom Oakley, Director of Drug Delivery Device Development, Springboard, will speak on the Strategies for Environmental Sustainability – looking in particular at the transition we are seeing to sustainability being seen as a primary concern for the drug delivery device industry.
Another environmental concern gaining increased traction is the medical waste generated at healthcare facilities. Most excitingly new innovations are now helping to overcomes this challenge. Mayur Patel, Digital Health Expert, PA Consulting explores the Duality of Safety and Efficacy in Green Drug Delivery. His session demonstrates how your company can join others leading ‘the economy of the future’ by focusing on minimizing waste and maximizing resources through reuse, distribution, and recycling.
The third track is entitled, Combination Products & Biologics, with four sessions featuring topics on packaging materials and regulations. One eagerly anticipated area is the future impact of mRNA technologies after the ground-breaking success of the two Covid vaccines. Tom Van Ginneken, Head of Product Management Polymer Solutions, SCHOTT AG will discuss the Long-Term Effects of mRNA Delivery, exploring the packaging considerations of such low temperature products.
In his insightful session on regulatory strategies, Fabien Roy, Partner, Hogan Lovells International LLP, will review the process and, considerations of, registering innovations so that they clear regulatory review and approval smoothly.
Finally, Asmita Khanolkar, Senior Director, Cambridge Pharma, SMC will discuss integrated approaches for the rapid development of novel therapies and the Dynamics and Outlook on High-Volume Subcutaneous Drug Delivery. Peter J. Schmitt, Managing Director & Co-Founder, Montesino will discuss The Limitations of Incumbent Materials. Exploring the intertwined challenges of Extractables and Leachables, and whether incumbent materials can meet the challenge or if it is time they are replaced by engineering grade polymers.
“Our events are now the tip of a 365 approach to industry partnering. Everything we do is about accelerating partnering and innovation process. So, in addition to the conference, we will be running a 2-day Symposium, Learning Lab presentations, the eponymous Awards ceremonies, as well as Start-up Hub, Innovation Gallery and tours,” added Ellis-Daal.
The 17 learning labs are a collection of short presentations on the latest drug delivery and device innovations, with highlights including, Aptar Pharma’s presentation on the ‘benefits of nasal drug delivery’ and West’s session on ‘selecting optimal pre-filled syringe components for Covid 19 vaccines’.
Additionally, the highly anticipated Pharmapack Report 2022 will be released at Pharmapack Europe, and is open for industry survey responses. To complete the survey and receive a pre-release copy of the findings, please visit: https://www.surveymonkey.co.uk/r/JWL5QB7
For more information on major industry trends or to register for the event, please visit, www.pharmapackeurope.com/en
Paris, 30 July 2020: Pharmapack Europe (#pharmapackeu), organised by Informa Markets, moves to May 2021 (19-20) to provide attendees, exhibitors and the pharma packaging community the best season and format. The decision follows a careful review with key stakeholders, with the exhibition continuing at its usual location: Hall 7.2 at Paris Expo, Porte de Versailles.
By announcing the rescheduling of the event early, the organizers hope to provide enough time to adjust travel plans and avoid unnecessary expenses. Additionally, stakeholders will be encouraged to take advantage of Pharmapack’s new suite of dedicated digital opportunities.
For example, the Global Pharma Insights platform features detailed content and analysis from many of the industry’s brightest experts, including high-quality packaging webinars, podcasts, reports, articles and more to help you network and stay up to date from the comfort of your own home.
Silvia Forroova, Brand Director at Pharmapack Europe commented: "We are in constant discussion with key industry stakeholders and Pharmapack partners to adjust how we deliver an event with the highest possible output and greatest value. So, we acted early and, by moving the event to springtime in Paris springtime, we will give ample time to adjust plans for what will be a magical and memorable edition of Pharmapack Europe.”
"Furthermore, to empower the dissemination of new ideas and technologies in the meantime, we will be providing our community with a carefully planned programme of digital opportunities to learn, connect, interact and stay completely abreast of the industry’s trends in the lead-up to the May event."
-ENDS-
Notes to editors
About Pharmapack
Launched in 1997, Pharmapack is the European event for Pharmaceutical Packaging, Drug Delivery, Medical Devices and Machinery. Pharmapack started as a biennial conference and exhibition, taking place every other year in Paris, until industry developments demanded a more frequent event to help the industry stay up to date on the latest trends, developments and regulations. In the past 20+ years, the event has grown from a conference with a small table-top exhibition, to an event hosting 411 exhibitors and welcoming 5,290 attendees over 2 days. In 2018, Pharmapack also featured the International Meetings Programme (business matching), an International Meetings Programme, full 2-day Conference, 1-day Symposium, Workshops, Learning Lab presentations, Awards ceremonies, a Start-up Hub, Innovation Gallery and Tours.
About Informa Markets
Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
For more information, please visit www.informamarkets.com.
The Informa Markets annual schedule of Pharmaceutical events include: CPhI & P-MEC India (26–28 November 2019 at the India Expo Mart, Greater Noida, Delhi NCR – Delhi, India); Pharmapack Europe (5-6 February, 2020 at the Paris Expo, Porte de Versailles – Paris, France); CPhI South East Asia (4-6 March, 2020 at the QSNCC – Bangkok, Thailand); CPhI Japan (16-18 March, 2020 at the Big Sight Exhibition Centre – Tokyo, Japan); CPhI North America (05 April - 07 May, 2020 at Pennsylvania Convention Centre – Philadelphia, USA); CPhI and P-MEC China (22-24 June, 2020 at SNIEC – Shanghai, China); CPhI Korea (26-28 August 2020), COEX – Seoul, Korea); CPhI Middle East & Africa (14-16 September, 2020 at the ADNEC – Abu Dhabi, United Arab Emirates); CPhI, ICSE, P-MEC, FDF, InnoPack Worldwide, BioProduction (13-15 October, 2020 at Fiera Milano, Milan)
For media enquiries, please contact:
Alex Heeley or Abdul Khalifeh
De Facto Communications
T: +44 (0) 203 735 8168
News and press releases relating to Pharmapack Europe 2021.
News and press releases relating to Pharmapack Europe 2020.
News and press releases relating to PharmaPack Europe 2019.
News and press releases relating to PharmaPack Europe 2018.
